Literature DB >> 31149094

TOPICAL STEROID INDUCED FACIAL ROSACEIFORM DERMATITIS.

A L Tatu1.   

Abstract

CONTEXT: Abuse of topical steroids on the face for long periods of time is a condition that needs time to cure and also methods to better observe the clinical features and for the follow-up after the cessation of steroids.
OBJECTIVES: To investigate which are the most prominent dermoscopic features of the Topical Steroid Induced Facial Rosaceiform Dermatitis(TSIFRD).
RESULTS: All 40 patients showed telangiectasias (100%) and dermoscopic polygonal vessels. 80% of the patients had dermoscopic features for Demodex Folliculorum, 80% had visible and dermoscopic pustules, 75 % had visible erythema on the face and by dermoscopy they all had red diffuse areas. The atrophy was clinically visible at 4 patients (Fig. 1a) as a severe skin thinning, but dermoscopy revealed also atrophic areas at another 4 as white structureless areas between vessels (Fig. 1b). The patients with dermoscopic atrophy were using 2 mometasone furoat, 6 clobetasol propionate - one of them in the periocular area developed a very strong clinically atrophy and also glaucoma but the cortisole levels were normal.
CONCLUSION: Dermoscopy is a tool for early detection of the infraclinical signs of TSIFRD by dermoscopic features: polygonal vessels, telangiectasias, scales, depressible erythema, pustules, Demodex plugs and tails, atrophy.

Entities:  

Keywords:  atrophy; dermoscopy; rosaceiform dermatitis; topical steroids

Year:  2016        PMID: 31149094      PMCID: PMC6535301          DOI: 10.4183/aeb.2016.232

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  1 in total

1.  Dermoscopy assisted topical steroid-dependent/damaged face (TSDF) severity score (DATS Score): Reliability assessment and validation of a new scoring method.

Authors:  Sheenam Sethi; Rashmi Jindal; Payal Chauhan
Journal:  Indian J Dermatol       Date:  2022 Mar-Apr       Impact factor: 1.757

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.